指南与共识儿童感染儿童呼吸

儿科医生对住院流感患儿奥司他韦推荐存在差异

Variability of Clinician Recommendations for Oseltamivir in Children Hospitalized With Influenza.
指南 / 共识 · Pediatrics · 2025-01-01

该横断面调查于2024年3月至6月在美国7家儿童医院开展,向5个专科的儿科医生发放包含4个符合2023年AAP抗病毒治疗指征临床情景的问卷。787名(42.7%)受邀者完成调查,受访者对49.5%(95%CI 47.0%-51.9%)的情景推荐奥司他韦,推荐率随医院和专科不同而异;症状持续时间较长和氧支持较少显著降低推荐可能性,知晓AAP推荐者中仍有38%未推荐治疗。

要点

  • 住院流感患儿中,儿科医生对符合AAP指征情景的奥司他韦推荐率平均仅49.5%。
  • 推荐率因医院(43.5%-64.2%)和专科(41.6%-70.9%)不同存在差异。
  • 症状持续时间较长和氧支持较少显著降低推荐奥司他韦的可能性。

核心结论

  • 儿科医生对住院流感患儿奥司他韦治疗存在不依从国家推荐和推荐差异,提示对哪些患者受益存在不确定性。

研究设计与样本

  • 2024年3月至6月在美国7家儿童医院开展的横断面调查,对象为5个专科的儿科医生。
  • 调查包含4个符合2023年AAP抗病毒治疗指征的临床情景,共1841人受邀,787人(42.7%)完成调查。

主要发现

  • 受访者对49.5%(95%CI 47.0%-51.9%)的情景推荐奥司他韦。
  • 推荐率按医院从43.5%到64.2%不等,按专科从41.6%(医院医学)到70.9%(感染病科)不等。
  • 症状持续时间较长和氧支持较少显著降低推荐奥司他韦的可能性。
  • 知晓AAP推荐增加推荐治疗的可能性,但知晓者中仍有38%未推荐治疗。
  • 87.4%的受访者认为住院儿童奥司他韦随机试验中度至极度重要。

关键数值与推荐

  • 2023年AAP标准:所有住院流感患儿均推荐抗病毒治疗。

临床怎么用

  • 临床医生应知晓对住院流感患儿奥司他韦推荐存在较大差异,需关注症状持续时间和氧支持程度对决策的影响。
  • 当前推荐缺乏高质量随机试验证据,临床决策需结合个体情况并期待随机对照试验结果。

局限性

  • 调查回复率为42.7%,可能存在无应答偏倚。
  • 研究为横断面调查,仅反映受访者的情景选择而非实际临床行为。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Although national recommendations advise antivirals for all hospitalized children with influenza, this recommendation is not supported by high-quality evidence like a randomized clinical trial, and recent data suggest nonadherence to guidelines. Our objective was to describe clinician treatment preferences for oseltamivir in hospitalized children. METHODS: This cross-sectional survey of pediatricians from 5 specialties was conducted at 7 US children's hospitals from March to June 2024. Four clinical vignettes meeting 2023 American Academy of Pediatrics (AAP) criteria for antiviral treatment were included. Our primary outcome was the average proportion of vignettes for which respondents recommended oseltamivir. RESULTS: Of 1841 invited participants, 787 (42.7%) completed surveys. Participants were likely to recommend oseltamivir for 49.5% (95% CI, 47.0%-51.9%) of cases; this varied by site from 43.5% to 64.2% and by specialty from 41.6% (hospital medicine) to 70.9% (infectious disease). Longer duration of symptoms and less oxygen support significantly decreased the likelihood of recommending oseltamivir. Awareness of AAP recommendations increased the likelihood of recommending treatment, although aware respondents did not recommend treatment in 38% of cases. Most respondents (87.4%) believed a randomized trial of oseltamivir in hospitalized children was moderately to extremely important. CONCLUSIONS: Our results demonstrate nonadherence to national recommendations and variability in oseltamivir treatment for children hospitalized with influenza, indicating uncertainty and disagreement regarding which patients benefit from antivirals. A randomized controlled trial of oseltamivir in hospitalized children is needed to help strengthen current influenza treatment recommendations and inform clinicians of treatment benefit in specific pediatric populations.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Bassett HK, Rao S, Beck J, et al. Variability of Clinician Recommendations for Oseltamivir in Children Hospitalized With Influenza. Pediatrics. 2025. PMID: 40274268. doi:10.1542/peds.2024-069111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。